Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
- PMID: 37731935
- PMCID: PMC10507198
- DOI: 10.1016/j.eclinm.2023.102193
Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
Abstract
Background: The causes for immune-mediated inflammatory diseases (IMIDs) are diverse and the incidence trends of IMIDs from specific causes are rarely studied. The study aims to investigate the pattern and trend of IMIDs from 1990 to 2019.
Methods: We collected detailed information on six major causes of IMIDs, including asthma, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, psoriasis, and atopic dermatitis, between 1990 and 2019, derived from the Global Burden of Disease study in 2019. The average annual percent change (AAPC) in number of incidents and age standardized incidence rate (ASR) on IMIDs, by sex, age, region, and causes, were calculated to quantify the temporal trends.
Findings: In 2019, rheumatoid arthritis, atopic dermatitis, asthma, multiple sclerosis, psoriasis, inflammatory bowel disease accounted 1.59%, 36.17%, 54.71%, 0.09%, 6.84%, 0.60% of overall new IMIDs cases, respectively. The ASR of IMIDs showed substantial regional and global variation with the highest in High SDI region, High-income North America, and United States of America. Throughout human lifespan, the age distribution of incident cases from six IMIDs was quite different. Globally, incident cases of IMIDs increased with an AAPC of 0.68 and the ASR decreased with an AAPC of -0.34 from 1990 to 2019. The incident cases increased across six IMIDs, the ASR of rheumatoid arthritis increased (0.21, 95% CI 0.18, 0.25), while the ASR of asthma (AAPC = -0.41), inflammatory bowel disease (AAPC = -0.72), multiple sclerosis (AAPC = -0.26), psoriasis (AAPC = -0.77), and atopic dermatitis (AAPC = -0.15) decreased. The ASR of overall and six individual IMID increased with SDI at regional and global level. Countries with higher ASR in 1990 experienced a more rapid decrease in ASR.
Interpretation: The incidence patterns of IMIDs varied considerably across the world. Innovative prevention and integrative management strategy are urgently needed to mitigate the increasing ASR of rheumatoid arthritis and upsurging new cases of other five IMIDs, respectively.
Funding: The Global Burden of Disease Study is funded by the Bill and Melinda Gates Foundation. The project funded by Scientific Research Fund of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (2022QN38).
Keywords: Global burden of disease study; Immune-mediated inflammatory disease; Incidence; Trend.
© 2023 The Author(s).
Conflict of interest statement
K Abuabara reports grants or contracts from Pfizer and Cosmetique Internacional SNC to their institution, University of California San Francisco; consulting fees from TARGET RWE; outside the submitted work. S Bhaskar reports leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, with the Rotary Club or Sydney as Board Director and Chair of Youth, with Rotary District 9675 as Chair of Diversity, Equity and Inclusion, and with Global Hub Health Germany as Founding Member and Co-manager, all outside the submitted work. R Buchbinder reports grants from Australian National Health and Medical Research Council (NHMRC), Arthritis Australia, Cabrini Foundation, HCF Foundation, Australian Department of Health to their institution; royalties or licenses from UptoDate as personal payments for a chapter on plantar fasciitis; all outside the submitted work. A K Demetriades reports leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, with European Association of Neurosurgical Societies (EANS) as President and with Global Neuro Foundation as Board Member, all outside the submitted work. I Filip and A Radfar report payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Avicenna Medical and Clinical Research Institute. T Fukumoto reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Eli Lilly, Sanofi, Pfizer, Maruho, Novartis, Taiho, Sun Pharma, UCB, and Janssen Pharma, all outside the submitted work. C Herteliu reports a research grant from Romanian Ministry of Research Innovation and Digitalization, MCID, for project titled “Enhancing institutional performance through development of infrastructure and transdisciplinary research ecosystem within socio-economic domain–PERFECTIS,” project number ID-585-CTR-42-PFE-2021, outside the submitted work. N Ismail reports leadership or fiduciary role in other board, society, committee or advocacy group, unpaid, with the Malaysian Academy of Pharmacy as council member and bursar, outside the submitted work. K Krishan reports non-financial support from UGC Centre of Advanced Study, CAS II, Department of Anthropology, Panjab University, Chandigarh, India, outside the submitted work. V Shivarov reports a pending Bulgarian patent for Possible SARS-CoV-2 preimmune epitopes; stock or stock options in ICON PLC through restricted stock units; other financial interests from PRAHS/ICON PLC through their salary; all outside the submitted work. C R Simpson reports research grants from MBIE (NZ), HRC (NZ), Ministry of Health (NZ), MRC (UK), HDRUK, and CSO (UK) to their institution, all outside the submitted work. J A Singh reports consulting fees from Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs Inc., Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications, the National Institutes of Health, and the American College of Rheumatology all as personal payments; payment or honoraria for speakers' bureaus from Simply Speaking; support for attending meetings or travel from the steering committee of OMERACT; unpaid participation on a Data Safety Monitoring Board or Advisory Board with the US Food and Drug Administration Arthritis Advisory Committee; leadership or fiduciary role in board, society, committee or advocacy group, paid or unpaid, with OMERACT as a steering committee member, with the Veterans Affairs Rheumatology Field Advisory Committee as Chair (unpaid), and with the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis and editor and director (unpaid); stock or stock options in Atai Life Sciences, Kintara Therapeutics, Intelligent Biosolutions, Acumen Pharmaceutical, TPT Global Tech, Vaxart Pharmaceuticals, Atyu Biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics, Tonix Pharmaceuticals Holding Corp., and Charlotte's Web Holdings, Inc., and previously owned stock options in Amarin, Viking, and Moderna Pharmaceuticals; all outside the submitted work. M Zielińska reports other financial or non-financial interests as an employee of AstraZeneca, outside the submitted work. E Upadhyay reports a published patent for A system and method of reusable filters for anti-pollution mask, A system and method for electricity generation through crop stubble by using microbial fuel cells, A system for disposed personal protection equipment (PPE) into biofuel through pyrolysis and method, A novel herbal pharmaceutical aid for formulation of gel and method thereof, and reports leadship for Joint Secretary of Indian Meteorological Society, Jaipur Chapter, India, Member Secretary-DSTPURSE Program.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10507198/bin/gr1.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10507198/bin/gr2.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10507198/bin/gr3.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10507198/bin/gr4.gif)
Similar articles
-
Global burden of inflammatory bowel disease 1990-2019: A systematic examination of the disease burden and twenty-year forecast.World J Gastroenterol. 2023 Nov 14;29(42):5751-5767. doi: 10.3748/wjg.v29.i42.5751. World J Gastroenterol. 2023. PMID: 38075848 Free PMC article.
-
Age-standardized incidence, prevalence, and mortality rates of autoimmune diseases in women of childbearing age from 1990 to 2019.Autoimmun Rev. 2023 Nov;22(11):103450. doi: 10.1016/j.autrev.2023.103450. Epub 2023 Sep 21. Autoimmun Rev. 2023. PMID: 37741529 Review.
-
The global incidence and disability of eye injury: an analysis from the Global Burden of Disease Study 2019.EClinicalMedicine. 2023 Aug 9;62:102134. doi: 10.1016/j.eclinm.2023.102134. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37599904 Free PMC article.
-
Temporal trends in the prevalence of autoimmune diseases from 1990 to 2019.Autoimmun Rev. 2023 Aug;22(8):103359. doi: 10.1016/j.autrev.2023.103359. Epub 2023 May 16. Autoimmun Rev. 2023. PMID: 37201621 Review.
-
Global, regional, and national burdens of HIV and other sexually transmitted infections in adolescents and young adults aged 10-24 years from 1990 to 2019: a trend analysis based on the Global Burden of Disease Study 2019.Lancet Child Adolesc Health. 2022 Nov;6(11):763-776. doi: 10.1016/S2352-4642(22)00219-X. Epub 2022 Sep 13. Lancet Child Adolesc Health. 2022. PMID: 36108664
Cited by
-
Personalized Management of Malignant and Non-Malignant Ectopic Mediastinal Thyroid: A Proposed 10-Item Algorithm Approach.Cancers (Basel). 2024 May 14;16(10):1868. doi: 10.3390/cancers16101868. Cancers (Basel). 2024. PMID: 38791947 Free PMC article. Review.
-
Identification of plasma protein markers of allergic disease risk: a mendelian randomization approach to proteomic analysis.BMC Genomics. 2024 May 22;25(1):503. doi: 10.1186/s12864-024-10412-0. BMC Genomics. 2024. PMID: 38773393 Free PMC article.
-
Homoharringtonine: updated insights into its efficacy in hematological malignancies, diverse cancers and other biomedical applications.Eur J Med Res. 2024 May 4;29(1):269. doi: 10.1186/s40001-024-01856-x. Eur J Med Res. 2024. PMID: 38704602 Free PMC article. Review.
-
Polymorphic markers of several immune regulatory genes modulate the susceptibility for eczema and related phenotypes in children.Transl Pediatr. 2024 Mar 27;13(3):436-446. doi: 10.21037/tp-23-474. Epub 2024 Mar 18. Transl Pediatr. 2024. PMID: 38590376 Free PMC article.
-
Causal role of immune cells in psoriasis: a Mendelian randomization analysis.Front Immunol. 2024 Mar 15;15:1326717. doi: 10.3389/fimmu.2024.1326717. eCollection 2024. Front Immunol. 2024. PMID: 38558803 Free PMC article.
References
-
- El-Gabalawy H., Guenther L.C., Bernstein C.N. Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl. 2010;85:2–10. - PubMed
-
- Baena-Diez J.M., Garcia-Gil M., Comas-Cufi M., et al. Association between chronic immune-mediated inflammatory diseases and cardiovascular risk. Heart. 2018;104(2):119–126. - PubMed
-
- Marrie R.A., Walld R., Bolton J.M., et al. Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases. Gen Hosp Psychiatry. 2018;53:65–72. - PubMed
-
- Aguero F., Gonzalez-Zobl G., Baena-Diez J.M., et al. Prevalence of lower extremity peripheral arterial disease in individuals with chronic immune mediated inflammatory disorders. Atherosclerosis. 2015;242(1):1–7. - PubMed
LinkOut - more resources
Full Text Sources